Clonazepam and melatonin remain principal treatments for RBD in synucleinopathies, but evidence is limited and inconsistent, with clonazepam raising safety concerns and melatonin showing inconsistent efficacy.
A systematic review of 18 studies evaluated pharmacological treatments for vPSG-confirmed RBD in synucleinopathies. Clonazepam showed possible benefit but raised safety concerns, while melatonin was better tolerated but had inconsistent efficacy. Evidence for other agents was preliminary, and larger randomized trials are needed.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Clonazepam and melatonin remain principal treatments for RBD in synucleinopathies, but evidence is limited and inconsistent, with clonazepam raising safety concerns and melatonin showing inconsistent efficacy. The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 47/100 (low).
The Claim
Clonazepam and melatonin remain principal treatments for RBD in synucleinopathies, but evidence is limited and inconsistent, with clonazepam raising safety concerns and melatonin showing inconsistent efficacy.
This conclusion is most relevant to: Patients with synucleinopathies (PD, PDD, DLB, MSA, and isolated RBD) with vPSG-confirmed RBD.
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Pharmacological treatments of REM sleep behaviour disorder in synucleinopathies: a systematic review of effectiveness and safety. (Sleep medicine, 2026) —
How It Works
The proposed biological pathway:
- ▸RBD involves loss of normal REM sleep muscle atonia, leading to dream-enactment behaviors.
- ▸Clonazepam and melatonin are commonly used to reduce RBD symptoms, though their mechanisms are not fully understood.
- ▸Clonazepam may act via GABAergic modulation, while melatonin may help regulate circadian rhythms and REM sleep.
- ▸Evidence from 18 studies shows inconsistent objective improvement, with subjective improvement more common.
Who Might Benefit
Evidence fit by population:
- ▸Patients with synucleinopathies (PD, PDD, DLB, MSA, and isolated RBD) with vPSG-confirmed RBD
Recommended Dose
N/A
Limitations & Caveats
Important context when interpreting this evidence:
- ▸Heterogeneity in study design, interventions, and outcomes prevented meta-analysis.
- ▸Only 18 studies met inclusion criteria, and evidence for most agents was preliminary.
- ▸Risk of bias was assessed but not fully reported in the abstract.
Frequently Asked Questions
What is the most effective treatment for RBD in Parkinson's disease?▼
The systematic review found limited and inconsistent evidence. Clonazepam and melatonin are commonly used, but clonazepam has safety concerns and melatonin's efficacy varies across phenotypes.
Is clonazepam safe for patients with synucleinopathies?▼
Clonazepam showed possible benefit but raised important safety concerns in vulnerable synucleinopathy populations, so caution is advised.
Does melatonin improve RBD symptoms?▼
Melatonin appeared better tolerated than clonazepam, but efficacy was inconsistent across synucleinopathy phenotypes, and evidence is insufficient for definitive conclusions.
What other treatments are being studied for RBD in synucleinopathies?▼
Other agents include pramipexole, cannabidiol, nelotanserin, ramelteon, rivastigmine, rotigotine, sodium oxybate, safinamide, and 5-hydroxytryptophan, but evidence is preliminary.
References
- 1.Byun JJ, Badrakalimuthu VR. “Pharmacological treatments of REM sleep behaviour disorder in synucleinopathies: a systematic review of effectiveness and safety..” Sleep medicine, 2026. PMID: 42623795 DOI: 10.1016/j.sleep.2026.109154